Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
Small Cell Lung Cancer (SCLC)
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2/3
- Patients
- 550 (planned)
- Started
- Dec 9, 2025
- Main results expected
- Jun 14, 2030
- Fully finished
- Mar 11, 2034
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 2: Confirmed Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1] based on the investigator's assessment
Measured over: Up to approximately 2 years after completion of study treatment of last study participant
Phase 2: Number of participants with treatment-emergent adverse events
Measured over: Up to 90 days after the last dose of treatment
Phase 3: Overall Survival (OS)
Measured over: Up to approximately 2 years after completion of study treatment of last study participant
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07226999 · record last updated 2026-10-08 · checked 2026-11-09 15:47 UTC